Brinsupri
Pharma

Insmed's Brinsupri comes up short in rhinosinusitis trial

Insmed's shares tumbled by 16% when it reported the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis without nasal polyps.
drugs 2025 2025 in pharma regulatory tracker pharma 2025

Regulatory tracker: Rubraca scores full prostate cancer approval

Dec 18, 2025 2:45pm
Medtronic Own It MiniMed campaign

Medtronic MiniMed campaign pushes people with T1D to ‘Own It’

Dec 18, 2025 12:05pm
Rybrevant

FDA approves J&J's new challenge to Tagrisso

Dec 18, 2025 10:40am
tandem bike bicycle ride cruise riders

Bicycle gets radiopharmaceutical push from UK uranium deal

Dec 18, 2025 10:13am
Back side of Capitol building

Biosecure Act heads to Trump's desk after Senate vote

Dec 17, 2025 4:45pm
More News

How Lilly's 2026 Olympics team-ups align with its own mission

Dec 17, 2025 4:45pm
Fierce Healthcare

Medical groups decry CDC's major child vaccine change

Dec 17, 2025 2:00pm

Intercept, on heels of Ocaliva pull, warns of 146 layoffs

Dec 17, 2025 1:58pm

Ionis ramps up Angelman syndrome awareness with Lifetime segment

Dec 17, 2025 12:23pm